Acordingt to this report, the US Federal Trade Commission has released the results of a 2012 study and found that there was a sharp increase in pay-for-delay deals in the pharmaceutical industry, in which brand name and generic drug copanies made deals to keep generics off the shelves. Also according to the study, the deals cost citizens “billions” of dollars a year and added to the deferal deficit. According to the FTC repirt, drug companies made 40 of these deals in FY2012 (which ended September 30, 2012), and noted that the number was “significantly higher” than the 28 pay-for-delay deals made in FY2011. The FTC also found that nearly half of those 40 deals involved brand name companies promising not to market AG products that compete with generic company’s products.
Full Content: Intellectual Property Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI